AQR Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

AQR Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-169	Closed	-$37K	–	2305
2018 Q3	$37K	Buy	169 +35	+26%	+$84K	﹤0.01%	2247
2018 Q2	$288K	Buy	+134	New	+$340K	﹤0.01%	2136
2015 Q1	–	Sell	-29	Closed	-$29K	–	2346
2014 Q4	$29K	Sell	29 -16	-36%	-$14.3K	﹤0.01%	2490
2014 Q3	$47K	Sell	45 -73	-62%	-$108K	﹤0.01%	2485
2014 Q2	$228K	Sell	118 -290	-71%	-$574K	﹤0.01%	2315
2014 Q1	$873K	Buy	408 +141	+53%	+$351K	﹤0.01%	1758
2013 Q4	$616K	Sell	267 -54	-17%	-$124K	﹤0.01%	1960
2013 Q3	$904K	Buy	321 +308	+2,369%	+$1.53M	﹤0.01%	1706
2013 Q2	$123K	Buy	+13	New	+$100K	﹤0.01%	2268

Other funds holding ONCT

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management's ONCT Position: Q4 2018 in Review

AQR Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2018, closing a stake of 169 shares — an estimated $37K sold.

AQR Capital Management first reported a position in ONCT in Q2 2013 and held it in 9 quarters. The position peaked at $904K in Q3 2013. 43 funds tracked by Wall St. Rank hold ONCT as of Q4 2018.

AQR Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
AQR Capital Management sold 169 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $37K.
AQR Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
AQR Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $904K in Q3 2013.
43 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2018.

Based on AQR Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.